Exhibit 10.1


 


 


 





	Dated  	9
    July 2020
	
         

        FI N° 86508, FI N° 87226, FI N°
        92628, and FI N° 82693

        Serapis N° 2016-0480

         

         

         

	
        Curetis
        GmbH

        (as
        Borrower)

        -
        and - 

        OpGen,
        Inc.

        (as
        Guarantor)

        -
        and - 

        Ares
        Genetics GmbH

        (as
        Guarantor)

        -
        and - 

        European
        Investment Bank

        (as
Bank) 



 





Amendment
and Restatement Agreement in relation to


the
Finance Contract dated 12 December 2016 as amended and restated by the First Amendment and Restatement Agreement dated 20 May 2019




 


 


Execution Version


 


 





 


F3/AMT/ODT/6695769


1M0186.000485


 


Hogan Lovells International LLP, Atlantic
House, Holborn Viaduct, London EC1A 2FG


 


 




    	  





    	 



    


 


Contents


ClausePage




	1.   Definitions and interpretation	1
	2.   Amendment and Restatement	2
	3.   Representations and warranties	2
	4.   Construction	3
	5.   Affirmation and further assurance	3
	6.   Miscellaneous	3
	7.   Governing law and jurisdiction	4


 


Schedules




	Conditions Precedent	 5



 
 


    	  





    	 



    


 


This
Agreement is made on 2020


Between:


		(1)	Curetis GmbH, a company incorporated in Germany, having its registered office at Max-Eyth-Strasse
42, 71088 Holzgerlingen, Germany (the "Borrower");



		(2)	OpGen, Inc., a company incorporated under the laws of the State of Delaware having its principal
executive office at 708 Quince Orchard Road, Gaithersburg Maryland 20878, USA ("OpGen);



		(3)	Ares Genetics GmbH, a company incorporated in Austria with company number FN 468899 H and
registered office at Karl-Farkas-Gasse 18, A-1030, Vienna, Austria ("Ares Genetics" and together with OpGen, the
"Guarantors"); and



		(4)	The European Investment Bank, having its seat at 100 boulevard Konrad Adenauer, L-2950 Luxembourg
(the "Bank").



Whereas:


		(A)	This Agreement is supplemental to a Finance Contract dated 12 December 2016 and made between the
Borrower and the Bank (as variously amended and restated including most recently pursuant to an Amendment and Restatement Agreement
dated 20 May 2019 (the "Existing Finance Contract")).



		(B)	The Existing Finance Contract is guaranteed by Curetis NV, Curetis USA (each as defined in the
Existing Finance Contract) and Ares Genetics, pursuant to the New Curetis NV Guarantee, the New Curetis USA Guarantee and the New
Ares Genetics respectively (each as defined in the Existing Finance Contract).



		(C)	The Borrower has notified the Bank that the Borrower has been purchased by OpGen (the "Acquisition").



		(D)	As a result of the Acquisition, all of Curetis NV's assets and liabilities (including, without
limitation, the shares of the Borrower) have been transferred to OpGen and the Parties acknowledge that, from the date of the Acquisition,
Curetis NV will no longer trade. The Parties also acknowledge that as a result of the Acquisition Curetis USA will no longer trade.



		(E)	In consideration for the Bank agreeing to the amendments affected by this Amendment and Restatement
Agreement, OpGen has agreed to guarantee the obligations of the Obligors under the Finance Documents (each as defined in the Amended
and Restated Finance Contract) pursuant to the terms of the OpGen Guarantee. OpGen is Party to this Agreement in order to acknowledge
the terms of the Amended and Restated Finance Contract.



		(F)	In addition, the Borrower has requested a further loan of EUR 5,000,000 to fund certain research
and product development costs in relation to the Borrower's project to develop diagnostic solutions for COVID-19.



		(G)	The Bank and the Borrower now therefore wish to amend the terms of the Existing Finance Contract
including: (1) by introducing the COVID-19 Tranche (as defined in the Amended and Restated Finance Contract); and (2) by amending
certain other provisions of the Existing Finance Contract to reflect the changes made to the structure of the Group (as defined
in the Existing Facility Agreement) as a result of the Acquisition.



 


 



    	  





    	 



    

 


It
is agreed as follows:


		1.	Definitions and interpretation



		1.1	Incorporation of defined terms: Unless otherwise provided (including in the rest of this
Clause 1) or unless the context otherwise requires, all words and expressions defined in the Existing Finance Contract shall
have the same respective meanings in this Agreement.



		1.2	Definitions: In this Agreement, the following expressions shall have the following meanings:



"Ares
Genetics Second Guarantee" means the guarantee and indemnity agreement dated 20 May 2019 entered into between the Bank
and Ares Genetics (as Guarantor) (referred to as the Ares Genetics Second Guarantee Agreement in the Amended and Restated Finance
Contract).


"Ares Genetics
Third Guarantee" means the guarantee agreement to be entered into between the Bank and Ares Genetics (as Guarantor) on
or around the date of this Agreement substantially in the form of the Ares Genetics Second Guarantee.


"Amended and
Restated Finance Contract" means the amended and restated finance contract in the form set out in the Appendix to this Agreement.


"CP Notification"
means the confirmation given by the Bank to the Borrower that the Bank has received (or has waived its requirement to receive)
all of the documents and/ or evidence set out in Schedule 1 (Conditions Precedent) in each case in form and substance satisfactory
to the Bank.


"Effective Date"
means the date that the Bank gives the CP Notification.


"OpGen Guarantee"
means the guarantee agreement to be entered into between the Bank and OpGen (as Guarantor) on or around the date of this Agreement.


"Party"
means a party to this Agreement.


"Supplemental
Documents" means the documents set out in paragraph 4 of Schedule 1 (Conditions Precedent).


		1.3	Construction of Schedules: All defined terms used in Schedule 1 (Conditions Precedent),
unless otherwise provided or unless the context otherwise requires, shall have the meaning attributed to them in the Amended and
Restated Finance Contract (whether or not the Effective Date shall have occurred).



		1.4	Incorporation of terms: The Interpretation
and Definitions section of the Existing Finance Contract shall apply to this Agreement as if it were expressly set out in this
Agreement with the necessary changes being made and with each reference in the Existing Finance Contract to "this Agreement"
(or to like references) being deemed to be a reference to this Agreement.







    	2  





    	 



    

 


 


		2.	Amendment and Restatement



Amendment
and restatement: On the Effective Date, the Existing Finance Contract shall be amended and restated on the terms set out in
the Amended and Restated Finance Contract.


		3.	Approval of dissolution of Curetis NV and Curetis USA



On
and from the Effective Date, the Bank consents to the dissolution of Curetis NV and Curetis USA.


		4.	Representations and warranties



		(a)	The Borrower represents and warrants that the Repeating Representations in the Amended and Restated
Finance Contract are true:



		(i)	as at the date of this Agreement (whether or not the Effective Date shall have occurred by such
date); and



		(ii)	as at the Effective Date,



by
reference to the facts and circumstances existing at such dates.


		(b)	Ares Genetics represents and warrants that the representations set out at articles 6.01 (a) to
(e), and (g) to (n) (in each case, inclusive) of the Ares Genetics Second Guarantee are true:



		(i)	as at the date of this Agreement (whether or not the Effective Date shall have occurred by such
date); and



		(ii)	as at the Effective Date,



by
reference to the facts and circumstances existing at such dates.


		(c)	OpGen represents and warrants that the representations set out at article 5.01 of the OpGen Guarantee
are true as at the Effective Date by reference to the facts and circumstances existing at such dates.



		5.	Construction



		5.1	Confirmation: Subject to Clause 2 (Amendment and Restatement) and except where inconsistent
with the provisions of this Agreement, the terms of the Existing Finance Contract are confirmed and shall remain in full force
and effect.



		5.2	Construction: As of and after the Effective Date, the Existing Finance Contract and this
Agreement shall be read and construed as one document and references in the Existing Finance Contract and in each of the Finance
Documents to the Existing Finance Contract shall be read and construed as references to the Existing Finance Contract as amended
and restated by this Agreement.



		5.3	Designation: This Agreement is hereby designated as a Finance Document.



		6.	Affirmation and further assurance



		6.1	Affirmation:



		(a)	The Borrower and each Guarantor confirms:



 






    	3  





    	 



    

 


		(i)	its knowledge and acceptance of the Amended and Restated Finance Contract coming into effect on
and from the Effective Date;



		(b)	In addition, Ares Genetics confirms that from the Effective Date:



		(i)	the guarantee given by it in the Ares Genetics Second Guarantee (as applicable) will continue in
full force and effect; and



		(ii)	such guarantee will extend to all obligations of the Borrower under the Amended and Restated Finance
Contract and the other Finance Documents.



		6.2	Binding nature: The Bank and the Borrower hereby agree that, with effect from the Effective
Date, they shall be bound by the terms of the Amended and Restated Finance Contract.



		6.3	Further assurance: The Borrower shall, at the request of the Bank and at its own expense,
do all such acts and things necessary or desirable to give effect to the amendments effected or to be effected pursuant to this
Agreement.



		7.	Release of Guarantees



		7.1	With effect from the Effective Date, the Bank:



		(a)	releases Curetis NV from:



		(i)	the Initial Guarantee Agreement; and



		(ii)	the Curetis NV Second Guarantee (each as defined in the Amended and Restated Finance Contract (whether
or not the Effective Date shall have occurred)); and



		(b)	releases Curetis USA from:



		(i)	the Curetis USA First Guarantee Agreement; and



		(ii)	the Curetis USA Second Guarantee Agreement (each as defined in the Amended and Restated Finance
Contract (whether or not the Effective Date shall have occurred)).



		8.	Miscellaneous



		8.1	Incorporation of terms: The provisions of
Article 10.04 (Non-Waiver), Article 11.10 (Counterparts), Article 11.04 (Place of performance), Article 11.08
(Invalidity), Article 11.09 (Amendments) of the Existing Finance Contract shall apply to this Agreement as if they
were expressly set out in this Agreement with the necessary changes being made and with each reference in the Existing Finance
Contract to "this Agreement" or like references being deemed to be a reference to this Agreement.



		8.2	Third party rights: A person who is not a Party has no right under the Contracts (Rights
of Third Parties) Act 1999 (the "Third Parties Act") to enforce or to enjoy the benefit of any term of this Agreement.



 






    	4  





    	 



    

 


9.           
Governing law and jurisdiction


		9.1	Governing law: This Agreement and any non-contractual obligations arising out of or in connection
with it are governed by and shall be construed and take effect in accordance with law of England and Wales.



		9.2	Jurisdiction: The provisions of Article 11.02 (Jurisdiction) of the Existing Finance
Contract shall be deemed to be incorporated herein as if set out in full in this Agreement with the necessary changes being made
and with each reference in the Existing Finance Contract to "this Agreement" (or like references) being construed as
references to this Agreement.



		9.3	Agent of Service: Without prejudice to any other mode of service allowed under any relevant
law, the Borrower hereby irrevocably appoints Vistra (UK) Ltd., 3rd Floor, 11-12 St James’s Square, London SW1Y 4LB, United
Kingdom as its agent of service for the purposes of accepting service on its behalf of any writ, notice, order, judgement or other
legal process. The Borrower agrees that failure by a process agent to notify it of the process will not invalidate the proceedings
concerned.



This Agreement has been entered
into on the date stated at the beginning of this Agreement


 


 




    	5  





    	 



    


Schedule
1


Conditions
Precedent


		1.	Borrower



		(a)	A copy of the constitutional documents of the Borrower.



		(b)	A copy of a resolution passed at a general meeting of the shareholders of the Borrower:



		(i)	approving the terms of the Supplemental Documents and resolving that it execute, deliver and perform
the Supplemental Documents to which it is a party;



		(ii)	authorising a specified person or persons to execute this Agreement on its behalf;



		(iii)	authorising a specified person or persons, on its behalf, to sign and/or despatch all documents
and notices to be signed and/or despatched by it under or in connection with the Supplemental Documents to which it is a party;
and



		(c)	A certificate of the Borrower (signed by an authorised signatory):



		(i)	confirming that borrowing or guaranteeing or securing, as appropriate, the Credit would not cause
any borrowing, guarantee, security or similar limit binding on the Borrower to be exceeded; and



		(ii)	certifying that each copy document relating to it specified in this Schedule 1 is correct, complete
and in full force and effect and has not been amended or superseded as at a date no earlier than the date of this Agreement.



		2.	OpGen



		(a)	A copy of the constitutional documents of OpGen.



		(b)	A copy of the Action by Unanimous Written Consent of the Board:



		(i)	approving the terms of the Supplemental Documents and resolving that it execute, deliver and perform
the Supplemental Documents to which it is a party;



		(ii)	authorising a specified person or persons to execute the Supplemental Documents to which it is
a party on its behalf;



		(iii)	authorising a specified person or persons, on its behalf, to sign and/or despatch all documents
and notices to be signed and/or despatched by it under or in connection with the Supplemental Documents to which it is a party;



		(c)	To the extent required by the Bank, a specimen of the signature of each person authorised by the
resolution referred to in paragraph (b) above;



		(d)	A certificate of OpGen (signed by an authorised signatory):



 






    	6  





    	 



    

 


		(i)	confirming that borrowing or guaranteeing or securing, as appropriate, the Credit would not cause
any borrowing, guarantee, security or similar limit binding on that Guarantor to be exceeded; and



		(ii)	certifying that each copy document relating to it specified in this Schedule 1 is correct, complete
and in full force and effect and has not been amended or superseded as at a date no earlier than the date of this Agreement.



		3.	Ares Genetics



		(a)	A copy of the constitutional documents of Ares Genetics.



		(b)	A copy of a resolution passed by the shareholder of Ares Genetics:



		(i)	approving the terms of the Supplemental Documents and resolving that it execute, deliver and perform
the Supplemental Documents to which it is a party;



		(ii)	authorising a specified person or persons to execute the Supplemental Documents to which it is
a party on its behalf;



		(iii)	authorising a specified person or persons, on its behalf, to sign and/or despatch all documents
and notices to be signed and/or despatched by it under or in connection with the Supplemental Documents to which it is a party;



		(c)	A certificate of Ares Genetics (signed by an authorised signatory):



		(i)	confirming that borrowing or guaranteeing or securing, as appropriate, the Credit would not cause
any borrowing, guarantee, security or similar limit binding on that Guarantor to be exceeded; and



		(ii)	certifying that each copy document relating to it specified in this Schedule 1 is correct, complete
and in full force and effect and has not been amended or superseded as at a date no earlier than the date of this Agreement.



		4.	Legal opinions



		(a)	A legal opinion of Hogan Lovells International LLP, legal advisors to the Bank as to English law,
substantially in the form distributed to the Bank prior to signing this Agreement.



		(b)	A legal opinion of CMS Hasche Sigle, Partnerschaft von Rechtsanwälten und Steuerberatern mbB,
legal advisers to the Borrower as to German law, on the valid existence of the Borrower, the authority and capacity of the Borrower
to enter into this Agreement, substantially in the form distributed to the Bank prior to signing this Agreement.



		(c)	A legal opinion of Ballard Spahr LLP, legal advisers to OpGen as to Delaware law, on the valid
existence of OpGen, the authority and capacity of OpGen to enter into the OpGen Guarantee and on the due execution of the OpGen
Guarantee, substantially in the form distributed to the Bank prior to signing this Agreement.



		(d)	A legal opinion of CMS Reich-Rohrwig Hainz Rechtsanwälte GmbH,
legal advisers to the Borrower as to Austrian law, on the valid existence of Ares Genetics, the authority and capacity of Ares
Genetics to enter into the Ares Genetics Third Guarantee and on the due execution of the Ares Genetics Third Guarantee, substantially
in the form distributed to the Bank prior to signing this Agreement.



 






    	7  





    	 



    

 


5.           
Supplemental Documents


		(a)	This Agreement, executed by the Parties.



		(b)	The OpGen Guarantee, executed by the Parties thereto.



		(c)	The Ares Genetics Third Guarantee, executed by the Parties thereto.



		6.	Other documents and evidence



		(a)	Evidence that the process agent referred to in clause 7.3 (Agent of Service) has accepted
its appointment; and evidence that the process agent referred to in the OpGen Guarantee and/or the Ares Genetics Third Guarantee
has accepted its appointment.



		(b)	A group structure chart of the Group as at the date of this Agreement.



		(c)	Evidence that any fees, costs and expenses then due from the Borrower have been paid or will be
paid by the Effective Date.



		(d)	A copy of any other Authorisation or other document, opinion or assurance which the Bank considers
to be reasonably necessary or desirable (if it has notified the Borrower accordingly) in connection with the entry into and performance
of the transactions contemplated by this Agreement or for the validity and enforceability of any Finance Document.



 




    	8  





    	 



    


Execution
Pages


The
Borrower 


Curetis GmbH


By:  /s/ Oliver
Schacht, Ph.D.


Name: Oliver Schacht, Ph.D.


Title: Managing Director


 


By:  /s/ Johannes
Bacher


Name: Johannes Bacher


Title: Managing Director


 


The
Guarantors


OpGen, Inc.


By: /s/ Oliver Schacht,
Ph.D. 


Name: Oliver Schacht, Ph.D.


Title: President & Chief
Executive Officer


 


By:  /s/ Timothy
C. Dec


Name: Timothy C. Dec


Title: Chief Financial Officer


 


 


 


 


 




    	9  





    	 



    


 


Ares Genetics GmbH


By:  /s/ Dr. Andreas
Posch


Name: Dr. Andreas Posch


Title: Managing Director and
Chief Executive Officer


 


By:  /s/ Dr. Achim
Plum


Name: Dr. Achim Plum


Title: Managing Director


 




    	10  





    	 



    


 


The
Bank


European
Investment Bank


acting
by its duly authorised signatory


 


By:  /s/ Garth
Grisbrook


Name: Garth Grisbrook


Title: Head of Division


 


 


By:  /s/
Imanol Lecue Gurtubay


Name: Imanol Lecue
Gurtubay


Title: Legal Counsel



 




    	11  





    	 



    


 


 


Appendix


 


The Amended and Restated Finance Contract


 


{*inserted overleaf*}